Medicare Advantage denials jumped again: here's the appeal math payers hope you never do

If it feels like your Medicare Advantage claims are getting denied more often than they used to, that is not perception drift. Industry claims data for 2024 show Medicare Advantage denials jumped 4.8% from 2023 to 2024, while commercial denials rose 1.5% over the same period. MA is not just participating in the broader denial trend; it is leading it by a factor of three. For any practice with a meaningful Medicare Advantage panel, this is now a line-item problem, not background noise.

The stakes per denial went up too

It would be one thing if MA plans were denying more small claims. They are not. Per MDaudit's 2025 analysis, the average denied Medicare Advantage claim is now worth roughly $1,000, up 22.4% year over year. Hold both numbers in your head at once: the frequency of MA denials is rising and the dollar value of the average denial is rising faster. A practice that shrugged off MA denials three years ago on the theory that each one was small money is operating on stale assumptions. The composition of what gets denied has shifted toward claims that actually matter.

This tracks with what finance leaders across healthcare are reporting. In HFMA's 2024 survey, 82% of healthcare CFOs said denials have increased significantly since before the pandemic. The people whose job is to watch the cash have already concluded this is a structural change, not a cycle.

Now do the expected-value math

Here is the calculation that should drive every MA denial decision, and it takes thirty seconds. Federal MA appeals data analyzed by KFF show that of denied MA claims that are actually appealed, roughly 54% to 57% get overturned. Not resubmitted and re-denied. Overturned, in the provider's or patient's favor, more than half the time.

Run it as a hypothetical. Take a denied MA claim at the MDaudit average of about $1,000. At a 55% overturn rate, the expected recovery from filing an appeal is roughly $550. Against that, put the cost of the appeal itself: MGMA, HFMA, and Change Healthcare estimates range from $25 for a simple rework, past $100 for a formal appeal, up to $118 to $181 at the high end. Even taking the most expensive estimate, the expected return on appealing a typical denied MA claim is around three to one. On the cheaper end of the cost range, it is better than four to one. There are very few places in practice operations where a documented, repeatable three-to-one return sits unclaimed. This is one of them.

An overturn rate above 50% carries a second, quieter message. If more than half of appealed denials get reversed, then a very large share of these denials were not defensible in the first place. The initial denial is not the payer's final answer. It is the payer's opening position, and the data say the opening position folds under scrutiny most of the time.

Why the math goes uncollected

Because almost nobody appeals. KFF research on the patient side found that fewer than 1% of patients ever appeal a denial. Provider-side appeal rates are better than that, but the unworked-denial problem documented across the industry makes clear they are nowhere near where a 55% overturn rate says they should be. The system's economics only function this way because appeals are rare. Every denial that goes unappealed resolves in the payer's favor at a cost of zero. A rational payer does not need any individual denial to be correct; it needs the aggregate appeal rate to stay low. So far, it has.

The practical barriers are real: appeal deadlines that vary by plan, documentation requirements that differ by denial reason, and staff who are already underwater. None of that changes the arithmetic. It just explains why the arithmetic goes uncollected, and why the practices that build a disciplined appeal process are effectively collecting money their peers are donating.

What a disciplined MA appeal process looks like

Four elements, none exotic. First, segmentation: every MA denial gets an expected-value tag on arrival: dollar amount, denial reason, and historical overturn likelihood for that reason. Second, deadline control: appeal windows tracked as hard dates in a queue someone owns, not as fields buried in the PM system. Third, templated evidence: the same handful of denial reasons account for most volume, so the supporting-documentation package for each should be assembled once and reused, cutting the per-appeal cost toward the bottom of that $25-to-$181 range. Fourth, escalation discipline: a first-level denial upheld on flimsy reasoning goes to the next appeal level rather than the write-off pile, because the overturn data include those later stages.

If you want to know what this math looks like on your own MA book (how many denials, at what average value, with how much appeal runway left), that is precisely what our Recovery Audit produces, and we currently run it at no charge for a limited number of practices each month. We quantify the recoverable value sitting in your denied claims and finish with a written go/no-go: a clear, documented answer on whether recovery work will pay for itself on your numbers. If the math does not work, the report says so, and wondering is the only thing it cost you.